KIRhub 2.0· v2

Paxalisib

f394b414-310c-5e9c-9854-85fd86372a64 · FDA Phase III Trials to begin · targets PI3K, MTOR_FRAP1

Paxalisib

MeasuredReference

Paxalisib targets CHEK1, MTOR_FRAP1. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

CHEK1 MTOR_FRAP1

Top hallmarks

tumor promoting inflammation1.4k
proliferation1.2k
evading apoptosis1.1k

Top pathways disrupted

apical junction2.6k
pi3k akt mtor signaling2.5k
allograft rejection2.4k

Resistance landscape — Paxalisib

MeasuredReference

1 known oncogenic variants exist on Paxalisib's top targets — see detail for inhibition impact.

RAF1 1 known variant
- RAF1 (R391W)

Open in new tab